AstraZeneca should not be overlooked for long
03/04/24 -"While AstraZeneca witnessed a phenomenal turnaround in the last decade, the share price has been quiet in the last two years as sentiment has been impacted by a range of factors including too-high ..."
Pages
65
Language
English
Published on
03/04/24
You may also be interested by these reports :
15/01/26
In late-2024, when we last teased the story of DiaSorin (BUY; Italy), a family-owned in-vitro diagnostic company specialising in immunodiagnostics ...
09/01/26
Hikma, over the years, has struggled to create shareholder wealth, perhaps because of its inability (until now) to develop biosimilars on its own. ...
31/12/25
Keeping in mind the underwhelming late-stage results of the immunology drug, amlitelimab, and a few other R&D setbacks in recent years, we have ...
30/12/25
Over the last three years, GSK’s earnings have exceeded the market’s expectations on most occasions. Moreover, the firm’s R&D efforts have yielded ...